tiprankstipranks
vTv Therapeutics (VTVT)
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price & Analysis

751 Followers

VTVT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$7.38 - $34.01
Previous Close$18.08
Volume2.14K
Average Volume (3M)10.38K
Market Cap
$54.42M
Enterprise Value$7.66M
Total Cash (Recent Filing)$52.26M
Total Debt (Recent Filing)$298.00K
Price to Earnings (P/E)
Beta0.91
Jul 31, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.87
Shares Outstanding3,010,206
10 Day Avg. Volume3,507
30 Day Avg. Volume10,375
Standard Deviation0.24
R-Squared0.02
Alpha-0.00202
Financial Highlights & Ratios
Price to Book (P/B)2.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.66
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

VTVT FAQ

What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was $7.38 and its highest was $34.01 in the past 12 months.
    What is vTv Therapeutics’s market cap?
    Currently, no data Available
    When is vTv Therapeutics’s upcoming earnings report date?
    vTv Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 48 days.
      How were vTv Therapeutics’s earnings last quarter?
      vTv Therapeutics released its earnings results on May 09, 2024. The company reported -$1.17 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.17.
        Is vTv Therapeutics overvalued?
        According to Wall Street analysts vTv Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does vTv Therapeutics pay dividends?
          vTv Therapeutics does not currently pay dividends.
          What is vTv Therapeutics’s EPS estimate?
          vTv Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does vTv Therapeutics have?
          vTv Therapeutics has 2,432,857 shares outstanding.
            What happened to vTv Therapeutics’s price movement after its last earnings report?
            vTv Therapeutics reported an EPS of -$1.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.131%.
              Which hedge fund is a major shareholder of vTv Therapeutics?
              Among the largest hedge funds holding vTv Therapeutics’s share is Baker Bros Advisors LP. It holds vTv Therapeutics’s shares valued at 2M.
                ---

                vTv Therapeutics Stock Smart Score

                Company Description

                vTv Therapeutics

                vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Cassava Sciences
                AnaptysBio
                Curis
                Eyenovia
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis